{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:42:13Z","timestamp":1793673733074,"version":"4.5.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01303-w","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T10:15:05Z","timestamp":1765620905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2"],"prefix":"10.1038","volume":"10","author":[{"given":"Jason P.","family":"Laliberte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuishu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Acton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Cadevilla","family":"Peano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Janney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinita","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giune","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seme","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hibret","family":"Adissu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawley","family":"Pruitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheyne","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh-Ming","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Francica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Esser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"1303_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","volume":"21","author":"PV Markov","year":"2023","unstructured":"Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361\u2013379 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1303_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat. Microbiol. 7, 423\u2013433 (2022).","journal-title":"Nat. Microbiol."},{"key":"1303_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq4130","volume":"14","author":"PS Arunachalam","year":"2022","unstructured":"Arunachalam, P. S. et al. Durable protection against the SARS-CoV-2 omicron variant is induced by an adjuvanted subunit vaccine. Sci. Transl. Med. 14, eabq4130 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1303_CR4","doi-asserted-by":"publisher","first-page":"m4836","DOI":"10.1136\/bmj.m4836","volume":"371","author":"JH Tanne","year":"2020","unstructured":"Tanne, J. H. Covid-19: Pfizer-BioNTech vaccine is rolled out in the US. BMJ 371, m4836 (2020).","journal-title":"BMJ"},{"key":"1303_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).","journal-title":"Int. J. Pharm."},{"key":"1303_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3389\/fimmu.2018.00598","volume":"9","author":"CM Snapper","year":"2018","unstructured":"Snapper, C. M. Distinct immunologic properties of soluble versus particulate antigens. Front. Immunol. 9, 598 (2018).","journal-title":"Front. Immunol."},{"key":"1303_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NAC Jackson","year":"2020","unstructured":"Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 5, 11 (2020).","journal-title":"NPJ Vaccines"},{"key":"1303_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00707-w","volume":"8","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery. NPJ Vaccines 8, 111 (2023).","journal-title":"NPJ Vaccines"},{"key":"1303_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902802","volume":"7","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. In vivo assembly of nanoparticles achieved through synergy of structure-based protein engineering and synthetic DNA generates enhanced adaptive immunity. Adv. Sci. 7, 1902802 (2020).","journal-title":"Adv. Sci."},{"key":"1303_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","volume":"53","author":"Y Kato","year":"2020","unstructured":"Kato, Y. et al. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 53, 548\u201363.e8 (2020).","journal-title":"Immunity"},{"key":"1303_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1021\/bc100367u","volume":"22","author":"KG Patel","year":"2011","unstructured":"Patel, K. G. & Swartz, J. R. Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. Bioconjug. Chem. 22, 376\u2013387 (2011).","journal-title":"Bioconjug. Chem."},{"key":"1303_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","volume":"40","author":"EVL Grgacic","year":"2006","unstructured":"Grgacic, E. V. L. & Anderson, D. A. Virus-like particles: passport to immune recognition. Methods 40, 60\u201365 (2006).","journal-title":"Methods"},{"key":"1303_CR13","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1586\/erv.10.115","volume":"9","author":"A Rold\u00e3o","year":"2010","unstructured":"Rold\u00e3o, A., Mellado, M. C., Castilho, L. R., Carrondo, M. J. & Alves, P. M. Virus-like particles in vaccine development. Expert Rev. Vaccines 9, 1149\u20131176 (2010).","journal-title":"Expert Rev. Vaccines"},{"key":"1303_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2022.130288","volume":"1867","author":"AA Reutovich","year":"2023","unstructured":"Reutovich, A. A., Srivastava, A. K., Arosio, P. & Bou-Abdallah, F. Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development. Biochim. Biophys. Acta Gen. Subj. 1867, 130288 (2023).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"1303_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102\u2013106 (2013).","journal-title":"Nature"},{"key":"1303_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41591-021-01660-8","volume":"28","author":"KV Houser","year":"2022","unstructured":"Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383\u2013391 (2022).","journal-title":"Nat. Med."},{"key":"1303_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade4790","volume":"15","author":"AT Widge","year":"2023","unstructured":"Widge, A. T. et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med. 15, eade4790 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1303_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","volume":"588","author":"Z Ke","year":"2020","unstructured":"Ke, Z. et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588, 498\u2013502 (2020).","journal-title":"Nature"},{"key":"1303_CR19","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1303_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","volume":"586","author":"C Mu\u00f1oz-Fontela","year":"2020","unstructured":"Mu\u00f1oz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509\u2013515 (2020).","journal-title":"Nature"},{"key":"1303_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41586-020-2772-0","volume":"588","author":"DJ Benton","year":"2020","unstructured":"Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327\u2013330 (2020).","journal-title":"Nature"},{"key":"1303_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0839","volume":"377","author":"AA Cohen","year":"2022","unstructured":"Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839 (2022).","journal-title":"Science"},{"key":"1303_CR23","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","volume":"56","author":"S Ols","year":"2023","unstructured":"Ols, S. et al. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity 56, 2425\u201341.e14 (2023).","journal-title":"Immunity"},{"key":"1303_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1303_CR25","doi-asserted-by":"crossref","unstructured":"Bachmann, M. F., van Damme, P., Lienert, F. & Schwarz, T. F. Virus-like particles: a versatile and effective vaccine platform. Expert Rev. Vaccines 24, 444\u2013456 (2025).","DOI":"10.1080\/14760584.2025.2508517"},{"key":"1303_CR26","first-page":"21","volume":"2024","author":"T Oyedele","year":"2024","unstructured":"Oyedele, T. et al. editors. Safety and immunogenicity of a SARS-CoV-2 mRNA virus-like particle vaccine in adults 18 years of age and older in a Phase I randomized clinical trial. Proc. Int. Soc. Vaccines 2024, 21\u201323 (2024).","journal-title":"Proc. Int. Soc. Vaccines"},{"key":"1303_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1126\/science.abd5223","volume":"370","author":"B Turo\u0148ov\u00e1","year":"2020","unstructured":"Turo\u0148ov\u00e1, B. et al. In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science 370, 203\u2013208 (2020).","journal-title":"Science"},{"key":"1303_CR28","unstructured":"Joyce M. G. et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 37, 110143."},{"key":"1303_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jmb.2003.07.013","volume":"333","author":"PB Rosenthal","year":"2003","unstructured":"Rosenthal, P. B. & Henderson, R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 333, 721\u2013745 (2003).","journal-title":"J. Mol. Biol."},{"key":"1303_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cyto.a.24501","volume":"101","author":"A Emmaneel","year":"2022","unstructured":"Emmaneel, A. et al. PeacoQC: Peak-based selection of high quality cytometry data. Cytom. A 101, 325\u2013338 (2022).","journal-title":"Cytom. A"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01303-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01303-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01303-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:53:52Z","timestamp":1766069632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01303-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01303-w","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.P.L., Y.C., T.K., Y.Z., K.R., K.R., D.F., R.R., O.A., V.C.P., N.J., V.P., S.S., A.P., G.P., S.D., H.A., H.P., Y.-H.C., G.T., M.N., J.G., P.S., J.R.F., M.E. are current employees of AstraZeneca and hold or may hold stock in AstraZeneca. R.C., C.K., Y.-M.L., and W.B. are previous employees of AstraZeneca and hold or may hold stock in AstraZeneca. AstraZeneca has filed patent applications (WO\/2024\/153794 and US20240277834) related to mRNA-VLP and mRNA vaccines. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}